IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Core Insights - IO Biotech is developing a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors, which may enhance treatment efficacy in cancer therapy [1][4] Presentation Details - The poster presentation titled "A TGF-β-directed peptide vaccine induces T cell activation & drives anti-tumor activity by modulating the architecture of the tumor microenvironment" will be presented by Dr. Matteo Bocci on February 25, 2025, at the AACR-IO conference [2] - The presentation will take place at JW Marriott Los Angeles, Platinum Ballroom A-E, from 1:45-4:00 PM PST [2] Research Findings - The TGF-β peptide vaccine, IO170, demonstrated significantly reduced tumor growth in models of pancreatic adenocarcinoma and prostate cancer, inducing robust immune responses without systemic toxicity [3] - The vaccine's mechanism involves reshaping the tumor microenvironment (TME) to enhance anti-tumor activity, contrasting with existing approaches that inhibit TGF-β signaling systemically [3][4] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company focused on immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its proprietary T-win platform [5] - The company is advancing its lead investigational cancer vaccine candidate, Cylembio™, which has received Breakthrough Therapy Designation from the FDA for advanced melanoma treatment in combination with Merck's KEYTRUDA [5]